Research programme: opioid receptor like-1 antagonists - Brane Discovery

Drug Profile

Research programme: opioid receptor like-1 antagonists - Brane Discovery

Alternative Names: 819555; 848814; BND-001; BND-1 programme; GSK 819555; GSK 848814; NiK-001; ORL-1 orphan receptor antagonists; ORL-1 programme; SB 612111

Latest Information Update: 11 Feb 2009

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Developer Brane Discovery
  • Class Small molecules
  • Mechanism of Action Adenylate cyclase stimulants; Calcium channel agonists; G protein-coupled receptor antagonists; Opioid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued CNS disorders; Neuropathic pain; Parkinson's disease

Most Recent Events

  • 12 Jun 2007 This programme is available for partnership opportunities (http://www.branediscovery.com)
  • 04 Jun 2007 Brane Discovery acquires this research programme from NiKem Research
  • 04 Jun 2007 Preclinical trials in Parkinson's disease in Italy (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top